AstraZeneca, Alexion close massive $39B merger; bluebird bio earns EU nod for Lenti-D as big split approaches
With the final hurdle recently cleared, AstraZeneca and Alexion can finally celebrate their $39 billion merger.
The drugmakers closed their major M&A pact Wednesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
